Literature DB >> 11123291

Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma.

N M Haynes1, M B Snook, J A Trapani, L Cerruti, S M Jane, M J Smyth, P K Darcy.   

Abstract

The structurally related TCR-zeta and Fc receptor for IgE (Fc epsilon RI)-gamma are critical signaling components of the TCR and Fc epsilon RI, respectively. Although chimeric Ab receptors containing zeta and gamma signaling chains have been used to redirect CTL to tumors, a direct comparison of their relative efficacy has not previously been undertaken. Here, in naive T lymphocytes, we compare the signaling capacities of the zeta and gamma subunits within single-chain variable domain (scFv) chimeric receptors recognizing the carcinoembryonic Ag (CEA). Using a very efficient retroviral gene delivery system, high and equivalent levels of scFv-zeta and scFv-gamma receptors were expressed in T cells. Despite similar levels of expression and Ag-specific binding to colon carcinoma target cells, ligation of scFv-anti-CEA-zeta chimeric receptors on T cells resulted in greater cytokine production and direct cytotoxicity than activation via scFv-anti-CEA-gamma receptors. T cells expressing scFv-zeta chimeric receptors had a greater capacity to control the growth of human colon carcinoma in scid/scid mice or mouse colon adenocarcinoma in syngeneic C57BL/6 mice. Overall, these data are the first to directly compare and definitively demonstrate the enhanced potency of T cells activated via the zeta signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11123291     DOI: 10.4049/jimmunol.166.1.182

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

1.  Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.

Authors:  James N Kochenderfer; Steven A Feldman; Yangbing Zhao; Hui Xu; Mary A Black; Richard A Morgan; Wyndham H Wilson; Steven A Rosenberg
Journal:  J Immunother       Date:  2009-09       Impact factor: 4.456

2.  Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.

Authors:  Jehonathan H Pinthus; Tova Waks; Victoria Malina; Keren Kaufman-Francis; Alon Harmelin; Itzhak Aizenberg; Hannah Kanety; Jacob Ramon; Zelig Eshhar
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

Review 3.  Applications of molecular engineering in T-cell-based immunotherapies.

Authors:  David A McBride; Matthew D Kerr; Shinya L Wai; Nisarg J Shah
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-04-10

4.  Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity.

Authors:  Junyun Lai; Sherly Mardiana; Imran G House; Kevin Sek; Melissa A Henderson; Lauren Giuffrida; Amanda X Y Chen; Kirsten L Todd; Emma V Petley; Jack D Chan; Emma M Carrington; Andrew M Lew; Benjamin J Solomon; Joseph A Trapani; Katherine Kedzierska; Maximilien Evrard; Stephin J Vervoort; Jason Waithman; Phillip K Darcy; Paul A Beavis
Journal:  Nat Immunol       Date:  2020-05-18       Impact factor: 25.606

5.  T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.

Authors:  Claudia Geldres; Barbara Savoldo; Valentina Hoyos; Ignazio Caruana; Ming Zhang; Eric Yvon; Michele Del Vecchio; Chad J Creighton; Michael Ittmann; Soldano Ferrone; Gianpietro Dotti
Journal:  Clin Cancer Res       Date:  2013-12-13       Impact factor: 12.531

6.  IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors.

Authors:  Lauren Giuffrida; Kevin Sek; Melissa A Henderson; Imran G House; Junyun Lai; Amanda X Y Chen; Kirsten L Todd; Emma V Petley; Sherly Mardiana; Izabela Todorovski; Emily Gruber; Madison J Kelly; Benjamin J Solomon; Stephin J Vervoort; Ricky W Johnstone; Ian A Parish; Paul J Neeson; Lev M Kats; Phillip K Darcy; Paul A Beavis
Journal:  Mol Ther       Date:  2020-07-21       Impact factor: 11.454

Review 7.  Hematopoietic stem cells for cancer immunotherapy.

Authors:  Eric Gschweng; Satiro De Oliveira; Donald B Kohn
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors:  Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

9.  Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells.

Authors:  A D Gritzapis; A Mamalaki; A Kretsovali; J Papamatheakis; M Belimezi; S A Perez; C N Baxevanis; M Papamichail
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

Review 10.  Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Authors:  Marc Cartellieri; Michael Bachmann; Anja Feldmann; Claudia Bippes; Slava Stamova; Rebekka Wehner; Achim Temme; Marc Schmitz
Journal:  J Biomed Biotechnol       Date:  2010-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.